 The receptor-interacting serine-slash-3 and in protein kinase-2, RIPK-2, plays an important role in both innate and adaptive immunity. It is also involved in the development of various cancers, making it a potential therapeutic target. Small molecule RIPK-2 inhibitors have been developed as a means of treating cancer with some successes reported. However, more research needs to be done before these drugs are ready for clinical use.